Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burden that cannot be ignored.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
01
2019
accepted:
17
07
2019
entrez:
1
8
2019
pubmed:
1
8
2019
medline:
5
3
2020
Statut:
epublish
Résumé
More than 20% of tuberculosis (TB) disease worldwide may be attributable to smoking and alcohol abuse. India is the second largest consumer of tobacco products, a major consumer of alcohol particularly among males, and has the highest burden of TB globally. The impact of increasing tobacco dose, relevance of alcohol misuse and past versus current or never smoking status on TB treatment outcomes remain inadequately defined. We conducted a multi-centric prospective cohort study of newly diagnosed adult pulmonary TB patients initiated on TB treatment and followed for a minimum of 6 months to assess the impact of smoking status with or without alcohol abuse on treatment outcomes. Smokers were defined as never smokers, past smokers or current smokers. Alcohol Use Disorder Identification Test (AUDIT) scores were used to assess alcohol misuse. The association between smoking status and treatment outcomes was assessed in univariate and multivariate random effects poisson regression models. Of 455 enrolled, 129 (28%) had a history of smoking with 94 (20%) current smokers and 35 (8%) past smokers. Unfavourable treatment outcomes were significantly higher among past and current smokers as compared to never smokers. Specifically, the risk of treatment failure was significantly higher among past smokers (aIRR = 2.66, 95% CI: 1.41-4.90, p = 0.002), recurrent TB among current smokers (aIRR = 2.94, 95% CI: 1.30-6.67, p = 0.010) and death among both past (2.63, 95% CI: 1.11-6.24, p = 0.028) and current (aIRR = 2.59, 95% CI: 1.29-5.18, p = 0.007) smokers. Furthermore, the combined effect of alcohol misuse and smoking on unfavorable treatment outcomes was significantly higher among past smokers (aIRR: 4.67, 95% CI: 2.17-10.02, p<0.001) and current smokers (aIRR: 3.58, 95% CI: 1.89-6.76, p<0.001). Past and current smoking along with alcohol misuse have combined effects on increasing the risk of unfavourable TB treatment outcomes. Innovative interventions that can readily address both co-morbidities are urgently needed.
Sections du résumé
BACKGROUND
More than 20% of tuberculosis (TB) disease worldwide may be attributable to smoking and alcohol abuse. India is the second largest consumer of tobacco products, a major consumer of alcohol particularly among males, and has the highest burden of TB globally. The impact of increasing tobacco dose, relevance of alcohol misuse and past versus current or never smoking status on TB treatment outcomes remain inadequately defined.
METHODS
We conducted a multi-centric prospective cohort study of newly diagnosed adult pulmonary TB patients initiated on TB treatment and followed for a minimum of 6 months to assess the impact of smoking status with or without alcohol abuse on treatment outcomes. Smokers were defined as never smokers, past smokers or current smokers. Alcohol Use Disorder Identification Test (AUDIT) scores were used to assess alcohol misuse. The association between smoking status and treatment outcomes was assessed in univariate and multivariate random effects poisson regression models.
RESULTS
Of 455 enrolled, 129 (28%) had a history of smoking with 94 (20%) current smokers and 35 (8%) past smokers. Unfavourable treatment outcomes were significantly higher among past and current smokers as compared to never smokers. Specifically, the risk of treatment failure was significantly higher among past smokers (aIRR = 2.66, 95% CI: 1.41-4.90, p = 0.002), recurrent TB among current smokers (aIRR = 2.94, 95% CI: 1.30-6.67, p = 0.010) and death among both past (2.63, 95% CI: 1.11-6.24, p = 0.028) and current (aIRR = 2.59, 95% CI: 1.29-5.18, p = 0.007) smokers. Furthermore, the combined effect of alcohol misuse and smoking on unfavorable treatment outcomes was significantly higher among past smokers (aIRR: 4.67, 95% CI: 2.17-10.02, p<0.001) and current smokers (aIRR: 3.58, 95% CI: 1.89-6.76, p<0.001).
CONCLUSION
Past and current smoking along with alcohol misuse have combined effects on increasing the risk of unfavourable TB treatment outcomes. Innovative interventions that can readily address both co-morbidities are urgently needed.
Identifiants
pubmed: 31365583
doi: 10.1371/journal.pone.0220507
pii: PONE-D-19-01166
pmc: PMC6668833
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220507Subventions
Organisme : NIAID NIH HHS
ID : R01 AI097494
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069465
Pays : United States
Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
The study team received funding (in kind) from Persistent Systems for development of a data management system that allowed online and offline data capture. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Hua Xi Yi Ke Da Xue Xue Bao. 2001 Mar;32(1):104-6
pubmed: 12733370
Lancet. 2003 Aug 16;362(9383):507-15
pubmed: 12932381
Br J Prev Soc Med. 1963 Jul;17:149-52
pubmed: 14044850
Thorax. 2008 May;63(5):440-6
pubmed: 17615085
BMC Public Health. 2007 Oct 14;7:291
pubmed: 17935630
Int J Tuberc Lung Dis. 2008 May;12(5):567-72
pubmed: 18419894
Int J Epidemiol. 2008 Aug;37(4):841-51
pubmed: 18556729
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
BMC Public Health. 2009 Aug 12;9:292
pubmed: 19674472
Am J Epidemiol. 2009 Dec 15;170(12):1478-85
pubmed: 19917554
Addiction. 2010 May;105(5):817-43
pubmed: 20331573
Euro Surveill. 2010 Mar 18;15(11):null
pubmed: 20338143
Int J Tuberc Lung Dis. 2011 Jun;15(6):838-43
pubmed: 21575308
PLoS One. 2011;6(5):e19485
pubmed: 21611189
PLoS One. 2011;6(11):e27752
pubmed: 22132134
PLoS One. 2012;7(7):e39443
pubmed: 22848354
Lancet Infect Dis. 2013 May;13(5):436-48
pubmed: 23531392
Int J Tuberc Lung Dis. 2014 Apr;18(4):492-8
pubmed: 24670708
PLoS One. 2014 May 02;9(5):e96433
pubmed: 24789311
South Asian J Cancer. 2014 Oct;3(4):200-2
pubmed: 25422803
Eur Respir J. 2015 Mar;45(3):839-42
pubmed: 25431269
BMC Public Health. 2015 Jan 21;15:13
pubmed: 25604986
Cold Spring Harb Perspect Med. 2015 Feb 06;5(11):null
pubmed: 25659380
Am J Med Sci. 2015 Jun;349(6):505-9
pubmed: 26030612
Bull World Health Organ. 2015 Jun 1;93(6):390-9
pubmed: 26240460
Chonnam Med J. 2015 Aug;51(2):86-90
pubmed: 26306303
Public Health Action. 2015 Sep 21;5(3):183-7
pubmed: 26399289
BMJ Open. 2016 Feb 25;6(2):e010542
pubmed: 26916698
BMJ Glob Health. 2016 Apr 6;1(1):e000005
pubmed: 28588906
Eur Respir J. 2017 Jul 13;50(1):
pubmed: 28705945
BMJ Open Respir Res. 2017 Oct 13;4(1):e000247
pubmed: 29071086
Lancet Respir Med. 2018 Apr;6(4):299-314
pubmed: 29595511
J Bras Pneumol. 2018 Apr;44(2):99-105
pubmed: 29791542
Expert Rev Respir Med. 2018 Jul;12(7):541-543
pubmed: 29799762
J Clin Tuberc Other Mycobact Dis. 2017 Aug;8:1-5
pubmed: 31008376